Related Experiment Video

Updated: Jun 27, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

Warren Fiskus, Rekha Rao, Ramesh Balusu

    Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
    |May 1, 2024
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
    10:26

    In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

    Published on: January 20, 2019

    12.2K
    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    12.1K

    Related Experiment Videos

    Last Updated: Jun 27, 2025

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    11.1K
    In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
    10:26

    In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

    Published on: January 20, 2019

    12.2K
    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    12.1K

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    4.9K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.6K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.6K

    Articles linked to this work by shared authors, journal, and citation graph.

    Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.

    Leukemia·2026

    Electrocatalytic Amide Synthesis: Mechanistic Pathways and Selectivity Control in C-N Coupling.

    Small (Weinheim an der Bergstrasse, Germany)·2026

    FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

    Research square·2026

    FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

    bioRxiv : the preprint server for biology·2026

    Dibutyl phthalate induces sarcopenia via TNFα/TNFR1-mediated proteolytic and pyroptotic axes: evidence from NHANES and experimental models.

    Frontiers in immunology·2026

    Congenital nephrotic syndrome with fulminant clinical course: A lesson for primary care physician.

    Journal of family medicine and primary care·2026

    HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodies.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosis.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Long-Term Outcomes and Biomarker Correlates of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    When the Tumor Disappears, Must the Larynx Follow?

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

    Current oncology (Toronto, Ont.)·2026

    Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

    Current oncology (Toronto, Ont.)·2026

    Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

    Current oncology (Toronto, Ont.)·2026

    [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

    Current oncology (Toronto, Ont.)·2026

    A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

    Current oncology (Toronto, Ont.)·2026

    A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

    Current oncology (Toronto, Ont.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us